Table 2.
Clinical course and follow-up of patients with revised diagnosis
| No | Age | Sex | Primary histology | Grade | TNM | Resection | Revised histology | Status/years |
|---|---|---|---|---|---|---|---|---|
| 1 | 60 | M | MEC | IG | pT4aN1 | R1 + RT | MASC HG | DOD/1 |
| 2 | 73 | M | ACa NOS | HG | pT3N0 | R1 + RT | MASC HG | L/NR/2,3,4 |
| 3 | 63 | M | ACa NOS | LG | pT3N0 | R1 + RT | MASC LG | NED/9 |
| 4 | 51 | K | AcCC | LG | pT2N0 | R0 | MASC LG | NED/7 |
| 5 | 75 | K | AcCC | LG | pT3N0 | R1 | MASC LG | NED/5 |
| 6 | 42 | K | Papillary CAC | LG | pT2N0 | R0 | MASC LG | NED/9 |
| 7 | 46 | K | UCa | IG | pT2N0 | R0 | NCa IG | NED/20 |
| 8 | 71 | K | SCC | HG | pT3N2b | Rx + RT | SDC HG | DOD/3 |
| 9 | 57 | M | CxPA | HG | pT4aN1 | R1 + RT | SDC HG | DOD/1 |
| 10 | 67 | M | MEC | HG | pT4aN2b | R1 + RT | SDC HG | DOD/2 |
| 11 | 47 | K | MEC | HG | pT4aN2b | Rx + RT | SDC HG | NED/20 |
| 12 | 48 | K | ACa NOS | IG | pT2N0 | R0 | AcCC LG | NED/19 |
| 13 | 62 | M | AdCC | HG | pT2N0 | R0 | AcCC HG | LNR/3 |
| 14 | 75 | M | MEC | IG | pT2N0 | R0 | EMCa LG | NED/6 |
| 15 | 52 | K | BCAca | LG | pT2N0 | R1 + RT | EMCa LG | LR/2,4,9 |
| 16 | 67 | M | AcCC | LG | pT2N0 | R0 | EMCa LG | NED/15 |
| 17 | 42 | M | CxPA (SDC) | HG | pT3N0 | Rx | CxPA in situ | NED/15 |
| 18 | 51 | M | CxPA (ACa NOS) | HG | pT2N0 | R0 | CxPA in situ | NED/9 |
| 19 | 40 | K | CxPA (ACa NOS) | pT2N0 | R0 | PA with SCM | NED/17 | |
| 20 | 71 | K | MEC | IG | pT2N0 | R0 | PA with SCM | DOC/10 |
| 21 | 42 | K | Clear cell Ca | LG | pT2N0 | Rx | Myoepithelioma | NED/9 |
| 22 | 56 | M | MEC | LG | pT2N0 | R0 | Metaplastic WT | NED/9 |
| 23 | 35 | K | PLGA | LG | pT2N0 | R1 | Necrotizing sialometaplasia | NED/5 |
| 24 | 70 | M | MEC | pT2N1 | R0; RT | SCC metastases (skin) | NED/6 | |
| 25 | 68 | M | Clear cell Ca | LG | pT2N0 | R0 | RCC metastases | DOD/2 |
| 26 | 65 | K | AcCC | LG | pT1N0 | R0 | RCC metastases | DOD/2 |
| 27 | 76 | K | AcCC | LG | pT2N0 | Rx | RCC metastases | AWD/4 |
| 28 | 75 | K | AcCC | LG | pT1N0 | R0 | BC metastases | NED/10 |
MASC mammary analogue secretory carcinoma, SDC salivary duct carcinoma, ACA NOS adenocarcinoma not otherwise specified, CxPA carcinoma ex pleomorphic adenoma, MEC mucoepidermoid carcinoma, SCC squamous cell carcinoma, AcCC acinic cell carcinoma, AdCC adenoid cystic carcinoma, EMCa epithelial–myoepithelial carcinoma, UCa undifferentiated carcinoma, PLGA polymorphous low-grade adenocarcinoma, NCa neuroendocrine carcinoma, CAC cystadenocarcinoma, RCC renal cell carcinoma, BC breast carcinoma, WT Warthin tumour, PA pleomorphic adenoma, SCM squamous cell metaplasia, HG high grade, IG intermediate grade, LG low grade, AWD alive with disease, NED no evidence of disease, DOD died of disease, DOC died of other cause, LR local recurrence, NR nodal recurrence, RT radiation therapy, R1 microscopically positive margin, Rx microscopically uncertain margin, R0 microscopically negative margin